Research programme: viral infections therapeutics - Aqualis
Alternative Names: CP-4018; ganciclovir elaidate - Aqualis; ganciclovir elaidic acid - AqualisLatest Information Update: 17 Nov 2013
At a glance
- Originator Clavis Pharma
- Developer Aqualis
- Class Hypoxanthines; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Herpes simplex virus infections; Viral infections
Highest Development Phases
- Discontinued Herpes simplex virus infections; Viral infections
Most Recent Events
- 29 Aug 2013 Discontinued - Preclinical for Herpes simplex virus infections in Norway (unspecified route)
- 29 Aug 2013 Discontinued - Preclinical for Viral infections in Norway (unspecified route)
- 07 Feb 2011 Research programme: viral infections therapy - Clavis is available for licensing as of 07 Feb 2011. http://www.clavispharma.com